Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 9Lymphoma, Follicular 5Recurrence 4Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, B-Cell, Marginal Zone 4Leukemia 4Lymphoma, Non-Hodgkin 3Multiple Myeloma 2Lymphoma 2Hematologic Neoplasms 2Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Lymphoma, B-Cell 1Leukemia, Plasma Cell 1Infectious Mononucleosis 1

Interventions

liposomal doxorubicin 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1auricularum 1Lenalidomide 1Doxorubicin 1Dexamethasone 1Calcium Dobesilate 1Bortezomib 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Leukemia, Plasma Cell × Bendamustine Hydrochloride × Clear all
NCT02315157 2025-10-15

Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma

Thomas Jefferson University

Phase 1 Withdrawn
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡